2024-02-15 14:05:19 ET
West Pharmaceutical Services, Inc. (WST)
Q4 2023 Earnings Conference Call
February 15, 2024 9:00 am ET
Corporate Participants
Quintin Lai - Vice President, Strategy and Investor Relations
Eric Green - Chair, President and Chief Executive Officer
Bernard Birkett - Senior VP and Chief Financial and Operations Officer
Conference Call Participants
David Windley - Jefferies
Paul Knight - KeyBanc Capital Markets
Jacob Johnson - Stephens
Derik De Bruin - Bank of America
Matt Larew - William Blair
John Sourbeer - UBS
Justin Bowers - Deutsche Bank
Larry Solow - CJS Securities
Presentation
Operator
Thank you for standing by, and welcome to West Pharmaceutical Services Fourth Quarter 2023 Earnings Conference Call. [Operator Instructions]
I would now like to hand the call over to Vice President, Strategy and Investor Relations, Quintin Lai. Please go ahead.
Quintin Lai
Thank you, Latif. Good morning, and welcome to West's Fourth Quarter and Full Year 2023 Conference Call. We issued our financial results this morning, and the release has been posted in the Investors section on the company's website located at westpharma.com.
This morning, we will review our financial results, provide an update on our business and present an update on our financial outlook for the full year 2024. There's a slide presentation that accompanies today's call, and a copy of the presentation is available on the Investors section of our website.
On Slide 4 is our Safe Harbor statement. Statements made by management on this call and in the accompanying presentation contain forward-looking statements within the meaning of U.S. federal securities law. These statements are based on our beliefs and assumptions current expectations, estimates and forecasts. The company's future results are influenced by many factors beyond the control of the company. Actual results could differ materially from past results as well as those expressed or implied in any forward-looking statement made here. Please refer to today's press release as well as any other disclosures made by the company regarding the risks to which it is subject including our 10-K, 10-Q and 8-K reports....
Read the full article on Seeking Alpha
For further details see:
West Pharmaceutical Services, Inc. (WST) Q4 2023 Earnings Call Transcript